Article and Video CATEGORIES
I just did a brief video that appears on my The Swedish hospital website/blog, addressing the question of why it is standard to give single agent but not doublet or other combinations to patients who have already received first line therapy for advanced NSCLC. As I cover in the video, the basic premise is that as treatment continues for patients on therapy for advanced NSCLC, it becomes only more and more important to balance the anticipated side effects of treatments against the incremental benefit of a more aggressive treatment. Overall, most patients with metastatic/advanced NSCLC can tolerate and benefit meaningfully from a combination approach for initial therapy (though a targeted therapy will be preferred for the vast majority of patients with a "driver mutation" such as an EGFR mutation or ALK rearrangement). But beyond that point, as patients are experiencing cumulative effects from both the treatment and often the underlying cancer, the evidence reveals that combinations confer greater side effects but no accompanying significant improvement in overall survival.
Instead, the prevailing standard of care, with the evidence to support it, is a strategy sequential single agent treatments, which may lead to further tumor shrinkage in some patients and prolonged stable disease in many others; these results often lead to an improvement in survival with a manageable balance of often modest side effects.
I welcome any questions or comments you might have.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…